Company: HCTI
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112544
Chunk: 14

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 14
---
                                                                                                                                                                              |

| (1) | The number of shares of common stock to be outstanding immediately                                                                      
 after this offering is based on 7,261,344 shares of our common stock outstanding as of November 14, 2025, and excludes as of such date: |

| ● | up to 1,429,528 shares of common stock issuable upon the exercise of the PIPE Warrants; |

| ● | up to 28,590 shares of common stock issuable upon the exercise 
 of the FA Warrants;                                            |

| ● | up to 23,905 shares of common stock issuable at an exercise 
 price of $20.916 upon the exercise of warrants;             |

| ● | up to 2,449 shares of common stock issuable at exercise price 
 of $2,654.34 upon the exercise of warrants;                   |

| ● | up to 1,436 shares of common stock issuable at exercise price 
 of $858.273 upon the exercise of warrants;                    |

| ● | up to 160,853 shares of common stock issuable upon the exercise                                                         
 of outstanding options awarded under our 2020 Stock Incentive Plan at a weighted exercise price of $8.58 per share; and |

| ● | the issuance of up to 3,839,147 shares reserved and remaining 
 available for issuance under our 2020 Stock Incentive Plan;   |

<div align='center'>S-5

RISK FACTORS</div>

Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should carefully consider the risk factors we describe below, together with other information in this prospectus supplement, the accompanying base prospectus and the information and documents incorporated by reference herein and therein, including our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025, and September 30, 2025, or any Annual Report on Form 10-K, Quarterly Report on Form 10-Q or a Current Report on Form 8-K that is incorporated by reference into this prospectus supplement and the accompanying base prospectus after the date of this prospectus supplement. Although we discuss key risks in those risk factor descriptions, additional risks not currently known to us or that we currently deem immaterial also may impair our business. Our subsequent filings